Heidelberg, 28 June 2007 – For the first time following the successful completion of the company’s restructuring process, SYGNIS Pharma AG today presented its consolidated annual report as at 31 March 2007. The sale of the bioinformatics unit in spring 2006 and the purchase of SYGNIS Bioscience GmbH & Co. KG in the second half of 2006 represent the company’s most important milestones on its way to becoming a pharmaceutical company, which focuses on the research, development and marketing of innovative therapies for the treatment of neurodegenerative disorders. As a result, a comparison of the report presented today with the details of the annual figures for the 2005/2006 fiscal year provides only a limited view of the overall picture.
